Pharmaceutical Advertising Rules in Canada: What's Allowed

Most marketing advice about pharmaceuticals is written for the United States — where you can put a branded prescription drug on television. In Canada, you cannot. If you market drugs, natural health products or medical devices to Canadians, the rules are different, stricter, and enforced before publication, not after.

This is a plain-English guide to what you can and cannot advertise in Canada — and, in the final section, what each rule means for your website and digital content.

---

Can you advertise prescription drugs in Canada?

No. Direct-to-consumer (DTC) advertising of prescription drugs is prohibited in Canada under the Food and Drugs Act. A manufacturer cannot both name a prescription drug and describe what it treats in the same message aimed at the public. Only products that Health Canada has authorized may be advertised at all.

This is a deliberate health-protection measure, and Canada is far from alone — DTC prescription-drug advertising is banned in nearly every industrialized country except the US and New Zealand.

---

What you can advertise: the three categories

Not all health products are treated the same way. Canadian rules sort them into distinct lanes:

1. Prescription (Rx) drugs — no consumer-facing promotion. You may state limited facts (name, price, quantity, dosage form) but no therapeutic claims to the public.
2. Over-the-counter (OTC) drugs and natural health products (NHPs) — advertisable to consumers, but only within the product’s authorization, and claims must not be false, misleading, or deceptive.
3. Medical devices — advertisable by class, with claims limited to the authorized intended use.

The governing principle, per Health Canada and Ad Standards’ consumer advertising guidelines: an ad cannot name a prescription product and describe its use to the public at the same time.

---

Advertising vs. “information”: the 2023 Health Canada guidance

The single most useful distinction for anyone publishing online is between advertising and non-promotional information.

• Advertising promotes the sale of a specific product → fully regulated.
• Information — factual education about a condition or treatment category that doesn’t push a branded product → falls outside advertising rules.

In 2023, Health Canada published revamped guidance on this distinction, clarifying when an activity crosses from information into advertising. This matters enormously for content marketing: a disease-awareness article is generally information, but the moment it steers readers toward a specific branded prescription product, it can become regulated advertising. (For the technical edge cases, the PAAB’s own Q&A is the reference.)

---

Who is PAAB, and is approval mandatory?

The Pharmaceutical Advertising Advisory Board (PAAB) is the independent, not-for-profit body recognized by Health Canada to preclear prescription-drug advertising directed at healthcare professionals — before it runs.

Is it mandatory? Strictly speaking, PAAB review is voluntary — but in practice it operates as mandatory. Medical publications and platforms require a PAAB approval number before they will run pharmaceutical advertising, and Health Canada relies on the system. Skipping it invites complaints and content removal.

On timing: a standard first submission is reviewed in about 10 business days, with shorter follow-up rounds until the material is accepted. Most submissions go through at least one revision, so budget several weeks.

---

Canada vs. the US: why FDA and HIPAA playbooks break here

This is where imported strategies fail. A US agency optimizes for a world where branded Rx ads are legal; a Canadian campaign built on that assumption is non-compliant on day one.

	United States	Canada
DTC Rx advertising	Legal (FDA-supervised)	Prohibited
Preclearance body	—	PAAB
Privacy framework	HIPAA	PIPEDA / Quebec Law 25
Governing law	FDA regulations	Food and Drugs Act

If a vendor cites HIPAA or FDA as your compliance framework, they are describing the wrong country. For a deeper breakdown, see our guide on entering the Canadian pharma market from the US.

---

What this means for your website and digital content

Rules are abstract until they hit a page. Here is where they actually bite:

• Product pages (Rx): must be intentionally lean — name, form, price are fine; therapeutic claims and testimonials are not. Compensate with rich unbranded educational content that captures informational search traffic legally.
• Metadata is promotional content. Title tags, meta descriptions and image alt text that pair a brand name with a benefit are treated as advertising. This is the most common silent violation.
• NHP claims must match the product’s Terms of Market Authorization — every on-page claim, not just the label.
• Blog and disease-education content is your safest, highest-leverage asset: as non-promotional information, it can be fully optimized without PAAB review — provided it stays unbranded.

This is why, in Canada, organic search and educational content are the strategic acquisition channel for regulated health brands: the channels US marketers lean on (DTC ads, aggressive paid search) are closed, and the compliant path rewards depth and authority.

---

This article is educational, non-promotional information about Canadian advertising rules. It names no branded prescription product in connection with its use — which is exactly what the rules above require.

If you want your health website to rank and stay compliant, that’s the entire focus of my practice. Get a free preliminary analysis of where your site stands.